

Understanding the effects of CMV on $\gamma\delta$ T-cell populations in HIV patients starting antiretroviral therapy

Authors:

Ibnu A Ariyanto^{a,b}, Silvia Lee^{c,d}, Riwanti Estiasari^{e,f}, Jeanne Edmands^d, Budiman Bela^b Amin Soebandrio^g, Patricia Price^{b,d}

^a Doctoral Program in Biomedical Science, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

^b Virology and Cancer Pathobiology Research Center, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

^c Department of Microbiology, Pathwest Laboratory Medicine, Perth, Australia.

^d School of Pharmacy & Biomedical Science, Curtin University, Perth, Australia.

^e Department of Neurology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

^f dr.Cipto Mangunkusumo Hospital, Jakarta, Indonesia

^g Eijkman Institute for Molecular Biology, Jakarta, Indonesia.

Background:

Cytomegalovirus (CMV) affects $\gamma\delta$ T-cell profiles in healthy individuals and transplant recipients. However the effects of HIV and CMV have not been distinguished in HIV patients, and were addressed here in Indonesian patients with a high burden of CMV.

Methods:

HIV patients ($n=40$) were studied before ART (V0) and after six months (V6), alongside healthy controls ($n=20$). 50% of patients had detectable CMV DNA at V0 and were grouped as CMV DNA+ or CMV DNA-. All participants were CMV-seropositive. Flow cytometry was used to assess proportions of $V\delta 2^-$ and $V\delta 2^+$ $\gamma\delta$ T-cells, their activation (HLA-DR) and terminal differentiation (CD27-/CD45RA+, CD57) and expression of NK cell-associated receptors (NKG2C, LIR1, CD16).

Results:

Proportions of $V\delta 2^-$ $\gamma\delta$ T-cells were high in HIV patients at V0 and declined at V6, remaining above levels in healthy controls. Proportions of $V\delta 2^+$ $\gamma\delta$ T-cells were uniformly low in patients, and the residual cells were enriched for markers of terminal differentiation. Proportions of $V\delta 2^+$ $\gamma\delta$ T-cells correlated inversely with levels of CMV DNA and CMV-reactive antibody. CMV reactive-antibody levels correlated with the expression of HLA-DR on $V\delta 2^+$ $\gamma\delta$ T-cells in CMV DNA- patients. There was no association between CMV metrics and proportions of TEMRA $\gamma\delta$ T-cells. CMV DNA+ patients showed a direct correlation between CMV reactive-antibody levels and $CD8^+$ $\gamma\delta$ T-cells at V0. This relationship that was reversed at V6.

Conclusions:

We demonstrate a role for CMV in the depletion of $V\delta 2^+$ $\gamma\delta$ T-cells in HIV patients beginning ART, but find no consistent evidence of a role for CMV in the activation of $\gamma\delta$ T-cells or their expression of markers of terminal differentiation. CMV may affect $\gamma\delta$ T-cell expression of CD8.

Disclosure Statement:

Nothing to disclose.

